Compass Therapeutics, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- CMPXCompass Therapeutics0Calm
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Running, no new patientsPhase 2/3168 patientsMain results: Aug 31, 2027 - CMPXCompass Therapeutics0Calm
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
FinishedPhase 249 patientsMain results: May 15, 2025 - CMPXCompass Therapeutics0Calm
Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
Not started yetPhase 258 patientsMain results: Sep 2028
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 2 purchases
- Lerner NeilChief Accounting Officer · Oct 1, 2026Bought 20,000 sharesabout $18 thousand ·
- Lerner NeilChief Accounting Officer · Sep 24, 2026Bought 2,500 sharesabout $3 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.